Jan 30 |
Dr. Reddy's GAAP EPS of $0.99, revenue of $867M
|
Jan 29 |
Dr. Reddy's Q3 2024 Earnings Preview
|
Jan 5 |
Journey Medical submits NDA for DFD-29 for rosacea
|
Jan 3 |
Dr. Reddy's acquires MenoLabs business from Amyris
|
Jan 3 |
Dr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women’s Health and Dietary Supplements Portfolio of Brands
|
Dec 29 |
Dr. Reddy's acquires 6.46% stake in Israeli biotech Edity Therapeutics
|
Dec 14 |
Dr. Reddy’s becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
|
Dec 11 |
Dr. Reddy's falls as FDA flags concerns on factory site
|
Dec 6 |
Dr Reddy's licenses Coya ALS candidate in exclusive deal
|
Dec 6 |
Coya Therapeutics, Inc. and Dr. Reddy’s Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|